logo

Quick Facts

Share

Delta Airlines Inc. (DAL) has agreed to pay $10.5 million to settle its alleged liability under the False Claims Act for falsely reporting information about the transfer of U.S. mail to foreign posts or other intended recipients under contracts with the U.S. Postal Service or USPS, the U.S. Justice Department...

3M (MMM) agreed to sell its rights to the Neoplast and Neobun brands and related assets in Thailand and certain other Southeast Asia countries, including the manufacturing assets of its Ladlumkaew, Thailand, facility to Selic Corp Public Company Limited (Selic), a company focusing on bonding innovation...

Booz Allen Hamilton Holding Corp. (BAH) said Thursday that it strongly disagreed with the U.S. Department of Justice's characterization of the proposed $440 million, approximately 500-person EverWatch Corp transaction. Booz Allen believe the acquisition would bring together two companies with complementary...

Siemens AG (SIEGY.PK, SMAWF) said it expects to book non-cash impairment of about 2.8 billion euros on its investment in Siemens Energy AG. Siemens said that, with Siemens Energy AG's Xetra closing share price of 13.99 euros on June 30, 2022, the market value of Siemens' 35% investment in Siemens...

JetBlue (JBLU) said that it has extended the expiration date of its tender offer to purchase all of the outstanding shares of common stock of Spirit Airlines Inc. (SAVE) for $30.00 per share, net to the seller in cash, without interest and less any required withholding taxes, to 5:00 p.m., New York City...

Takeda's takhzyro or lanadelumab demonstrated positive results in the prevention of hereditary angioedema attacks in phase 3 SPRING study in children ages 2 to less than 12 years. In this study, hereditary angioedema patients received a dose of 150 milligrams (mg) every 4 weeks in patients 2 to less...

Novartis (NVS) said, in early June, the company restarted radioligand therapy production at its sites in Ivrea, Italy, and Millburn, New Jersey, and resumed delivery of doses to patients in a phased approach. Novartis expects that product supply may be initially limited. The company has also restarted...

NeuroSense Therapeutics Ltd. (NRSN) reported results from a biomarker study conducted to evaluate the potential of CogniC, the company's combination drug for the treatment of Alzheimer's disease. The company said the biomarker study identified several biomarkers associated with AD, which indicate CogniC's...

Smith+Nephew (SNN, SN.L) said that the first robotic-assisted surgery using its LEGION CONCELOC Cementless Total Knee System was performed by Cyna Khalily, an orthopaedic surgeon specializing in adult reconstructive surgery of the hip and knee in Louisville, KY. According to the company, LEGION CONCELOC...

Biopharmaceutical company Ardelyx, Inc. (ARDX) announced Thursday that the company may receive up to $20 million from HealthCare Royalty Partners from the sale of its future royalties and sales milestones from Kyowa Kirin Co., Ltd., its collaboration partner in Japan for the commercialization of tenapanor...

Beverage alcohol company Constellation Brands (STZ, STZ.B) announced Thursday that following the recommendation of a special committee comprised solely of independent directors, its Board of Directors has approved, and will recommend to shareholders for approval, a proposal to eliminate the company's...

While reporting financial results for the first quarter of fiscal 2023 on Thursday, beverage alcohol company Constellation Brands, Inc. (STZ) maintained its comparable earnings guidance for the full-year 2023. For fiscal 2023, the company now projects earnings in a range of $10.50 to $10.80 per share...

Blueprint Medicines Corp. (BPMC) announced strategic financing collaborations with Sixth Street and Royalty Pharma (RPRX) for up to $1.25 billion. The company said the financings provide capital to expand and advance its pipeline towards commercialization and to continue pursuing strategic and synergistic...

Pfizer Inc. (PFE) announced Thursday the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for both vaccinated and unvaccinated patients who are at high risk for progression to...

Sanofi (SNY) on Thursday said that the U.S. Food and Drug Administration (FDA) has put partial clinical hold on Phase 3 studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis due to some cases of drug-induced liver injury found in patients enrolled in these studies . Consequently,...

Follow RTT